Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 770

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 7
Chunk 770
---
 loss
can be reasonably estimated. The Company, in accordance with this guidance, does not recognize gain contingencies until realized or realizable.

Earnings
per Share

Earnings
(loss) per share is computed in accordance with ASC Topic 260, “Earnings per Share” Basic weighted-average number
of shares of common stock outstanding for the year ended December 31, 2024 and December 31, 2023 include the shares of the Company issued
and outstanding during such period, on a weighted average basis. The basic weighted average number of shares of common stock outstanding
excludes common stock equivalents such as stock options and warrants, while diluted weighted average number of shares outstanding includes
such stock options and warrants. As of December 31, 2024 there were 1,763,750 stock warrants and 4,235,666 stock options that were not
included in the computation of diluted earnings per share, because to do so would have an antidilutive effect. As of December 31, 2023
there was 1,763,750 stock warrants and 1,215,001 stock options that were not included in the computation of diluted earnings per share,
because to do so would have an antidilutive effect.

Recent
Accounting Pronouncements 

In
November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No.
2023-07, “Improvements to Reportable Segment Disclosures (Topic 280)” which is intended to improve reportable segment disclosure
requirements, primarily through incremental disclosures of segment information on an annual and interim basis for all public entities.
The ASU expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly
provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description
of its composition for other segment items and interim disclosures of a reportable segment’s profit or loss and assets. The ASU
is to be applied retrospectively to all prior periods presented in the financial statements and is effective for our Annual Report on
Form 10-K for the fiscal year ended December 31, 2024, and interim periods thereafter. The Company adopted this guidance with no material
impact on its consolidated financial statements. See Note 9.

Recent
Accounting Pronouncements Not Yet Adopted 

In
November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income